DURABLE Clinical Trial Results Show GlycoMark is Key Test for Managing Patients wit...(l elevatedpostprandial spikes which are ...),Health

In a retrospective examination of studies (see below) evaluating the use of GlycoMark to monitor exenatide, pramlintide, sitagliptin, and biphasic insulin therapies, GlycoMark reflected changes in after-meal glucose levels more dynamically than A1C in moderately controlled patients - underscoring the ability of GlycoMark to detect underlying treatment effects on after-meal glucose not revealed by A1C. The study, "The Use of 1,5-Anhydroglucitol (GlycoMark) to Monitor New Classes of Therapies for Managing Post-meal Glucose in Patients with Diabetes," was presented at the recent American Association of Clinical Endocrinologists 2008 annual meeting in Orlando, Florida. Authors of the study included Steven Wittlin (University of Rochester), Toshikazu Yamanouchi (Teikyo University School of Medicine) and Antonio Ceriello (Warwick Medical School).

Exenatide Improves Postprandial Glucose (PPG) Control in Patients With Type 2 Diabetes as Measured by 1,5-Anhydroglucitol (GlycoMark)

Reference: Scientific Sessions of the American Diabetes Association - 2007 (David Kendall)

1,5-Anhydroglucitol (GlycoMark), a PPG Excursion Marker In Pramlintide-Treated Subjects

Reference: American Association of Clinical Endocrinologists 2007 Annual Meeting (Cameron Lush)

Efficacy and Safety of Sitagliptin Monotherapy in Japanese Patients with Type 2 Diabetes

Reference: Diabetes Research and Clinical Practice 2008 (Kenji Noaka)

Does serum 1,5-AG establish a relationship between improvements in HbA1c and postprandial glucose excursions? Supportive evidence utilizing the differential effects between biphasic insulin aspart 30 and insulin glargine.

Reference: Diabetic Medicine 2008 (Alan Moses)

About GlycoMark

Glyc
'/>"/>